The three-building facility enables JN to expand its ability to increase vaccine supplies. The move is intended to help reduce time to market for the company's Meningococcal meningitis serotypes A, C, Y and W-135.
Companies in this press-release
JN-Intl. acquires vaccine facilities from Pfizer
Biopharmaceutical firm JN Intl.acquired Biocor, a subsidiary of Pfizer, Inc.
Jun 2, 2009
See What’s Possible in Life Sciences Packaging at PACK EXPO International
Explore new machinery & materials from 2,600 exhibitors. Gain insights from 150+ free educational sessions. Find solutions to tackle the toughest challenges—for life sciences & beyond—at North America’s largest packaging & processing event.
REGISTER NOW & SAVE
